Belviq in 2005

Belviq Lorcaserin weight loss tablets in 2005

In May 2005, the first results of the second phase of Belviq clinical trials were published. Clinical trials “2a” demonstrated that a single dose of Belviq 15mg, taken within 4 weeks:

Provides about 3 pounds (1.36 kg) of weight loss.
May cause diarrhea, nausea, nasopharyngitis and cough.
Does not cause any change in the pressure of pulmonary artery and does not affect the heart valves.

In June 2005, another stage (“2b”) began and ended in August 2005. All the patients that participated in this research did not received any instruction on how to keep a diet and increase the physical activity, yet they were obliged to quit drinking alcohol.

The results of this clinical research have shown that the daily dose of:

  1. Belviq 10mg helps to reduce the body weight by 1.8 kg per 12 weeks.
  2. Belviq 15mg helps to reduce the body weight by 2.7 kg per 12 weeks.
  3. Belviq 20mg (10mg in the morning and 10mg in afternoon) reduces the body weight by 3.6 kg per 12 weeks.

In more than 5% of patients, participating in the “2b” clinical trial, Belviq (Lorcaserin) caused:

  • headache,
  • dizziness,
  • dry mouth,
  • nausea,
  • vomiting,
  • diarrhea,
  • nasopharyngitis,
  • urinary tract infection and fatigue.

In 2005, the molecular formula of Lorcaserin (the active ingredient of Belviq pills) was patented in EU and the USA. The anorexigenic agent Lorcaserin acquired:

  • The EU patent number 03 718 323
  • The US patent number 6.953.787

According to the Annual CONNECT MIP Ceremony 2005, Lorcaserin was recognized as the Most Innovative New Product!

Leave a comment

Your email address will not be published. Required fields are marked *